NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
18.82
-0.08 (-0.44%)
Jul 22, 2024, 10:00 AM EDT - Market open
NAMS Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$33.25
Upside
+76.70%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +64.74% | Jun 7, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | May 15, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +86.00% | Mar 14, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +86.00% | Mar 13, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $31 | Buy | Maintains | $25 → $31 | +64.74% | Feb 29, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +59.43% | Jan 18, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $37 | Buy | Initiates | $37 | +96.63% | Jan 16, 2024 |
| RBC Capital | RBC Capital | Buy Initiates $25 | Buy | Initiates | $25 | +32.86% | Oct 30, 2023 |
| Credit Suisse | Credit Suisse | Buy Maintains $21 → $22 | Buy | Maintains | $21 → $22 | +16.92% | Apr 3, 2023 |
| Credit Suisse | Credit Suisse | Buy Initiates $21 | Buy | Initiates | $21 | +11.60% | Jan 6, 2023 |
| SVB Leerink | SVB Leerink | Buy Initiates $19 | Buy | Initiates | $19 | +0.97% | Dec 20, 2022 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Dec 19, 2022 |
| Jefferies | Jefferies | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +27.54% | Dec 19, 2022 |